Related Experiment Video
Updated: Apr 29, 2026

Improved Enzyme Protection Assay to Study Staphylococcus aureus Internalization and Intracellular Efficacy of Antimicrobial Compounds
Published on: September 8, 2021
Epidermal growth factor receptor inhibitors selectively inhibit the expressions of human β-defensins induced by
Kio Park1, Rie Ommori2, Kyoko Imoto2
1Department of Dermatology, Yamato Takada Municipal Hospital, Nara, Japan; Department of Dermatology, Nara Medical University, Nara, Japan.
Background:
Epidermal growth factor receptor inhibitors (EGFRIs) have developed as one of the potential treatment options for various kinds of cancers. Although a variety of dermatological adverse reactions such as follicular acneiform eruptions is commonly encountered, the mechanism of the reactions remains unclear.
Objectives:
We investigated the effects of EGFRIs on the expression of human β-defensins against staphylococci to study the pathomechanism of cutaneous adverse reactions caused by EGFRIs.
Methods:
We investigated the expressions of human β-defensins 1, 2, and 3 (hBD1, 2, and 3) from staphylococci-stimulated normal human epidermal keratinocytes (NHEKs) cultured with or without the effects of two EGFRIs, gefitinib and erlotinib. We stimulated NHEKs with the supernatant of Staphylococcus aureus (S. aureus) and S. epidermidis and the live staphylococci. We measured hBDs in the culture supernatants of NHEKs by enzyme-linked immunosorbent assay (ELISA).
Results:
EGFRIs did not suppress the expressions of hBD1 and 3 induced by S. aureus. In contrast, EGFRIs suppressed the expressions of hBD2 and 3 induced by S. epidermidis.
Conclusion:
EGFRIs may cause cutaneous adverse effects through selectively perturbing innate immune responses induced by commensal and pathogenic bacteria.
Insights
Epidermal growth factor receptor inhibitors (EGFRIs) can alter skin immunity. These cancer drugs may cause side effects by affecting human beta-defensins (hBDs) in response to bacteria.
Area of Science:
- Dermatology
- Oncology
- Immunology
Background:
- Epidermal growth factor receptor inhibitors (EGFRIs) are used to treat various cancers.
- Dermatological side effects, like acneiform eruptions, are common with EGFRIs, but their mechanisms are unclear.
Purpose of the Study:
- To investigate how EGFRIs affect human beta-defensin (hBD) expression against staphylococci.
- To elucidate the pathomechanism of EGFRIs-induced cutaneous adverse reactions.
Main Methods:
- Human beta-defensins 1, 2, and 3 (hBD1, hBD2, hBD3) expression was studied in normal human epidermal keratinocytes (NHEKs).
- NHEKs were stimulated with Staphylococcus aureus and S. epidermidis (live or supernatant) with or without gefitinib and erlotinib (EGFRIs).
- hBD levels in culture supernatants were measured using enzyme-linked immunosorbent assay (ELISA).
Main Results:
- EGFRIs did not inhibit hBD1 and hBD3 expression induced by S. aureus.
- EGFRIs suppressed hBD2 and hBD3 expression induced by S. epidermidis.
Conclusions:
- EGFRIs may induce cutaneous adverse effects by selectively disrupting innate immune responses.
- This disruption involves altered responses to both commensal and pathogenic bacteria.
Related Concept Videos
Inhibitors of Gram-positive Cell Wall Synthesis
Clinical Significance of Antibiotic Resistance
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Staphylococcal Skin Infections
Mechanism of Antibiotic Resistance in MRSA
Gene Regulation in Microbial Communities: Quorum Sensing

